ES2934341T3 - Combinaciones de inhibidores de FGFR4 y secuestrantes de ácidos biliares - Google Patents

Combinaciones de inhibidores de FGFR4 y secuestrantes de ácidos biliares Download PDF

Info

Publication number: ES2934341T3
Authority: ES; Spain
Prior art keywords: alkyl; carboxamide; methyl; fgfr4; bile acid
Prior art date: 2016-11-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES17812269T

Other languages

English (en)

Spanish (es)

Inventor

Robin Alec Fairhurst

Porta Diana Graus

Jacqueline Kinyamu-Akunda

Andreas Joerg Mahl

Luigi Manenti

Andreas Weiss

Armin Wolf

Kuno Wuersch

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-02

Filing date

2017-11-01

Publication date

2023-02-21

2017-11-01 Application filed by Novartis AG filed Critical Novartis AG

2023-02-21 Application granted granted Critical

2023-02-21 Publication of ES2934341T3 publication Critical patent/ES2934341T3/es

Status Active legal-status Critical Current

2037-11-01 Anticipated expiration legal-status Critical

Links

102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 title claims abstract description 55
101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 title claims abstract description 53
229920000080 bile acid sequestrant Polymers 0.000 title claims abstract description 41
239000003112 inhibitor Substances 0.000 title description 11
229940096699 bile acid sequestrants Drugs 0.000 title description 7
238000002560 therapeutic procedure Methods 0.000 claims abstract description 34
230000000694 effects Effects 0.000 claims abstract description 33
229940125408 FGFR4 inhibitor Drugs 0.000 claims abstract description 31
230000005764 inhibitory process Effects 0.000 claims abstract description 31
238000011282 treatment Methods 0.000 claims abstract description 18
229920001268 Cholestyramine Polymers 0.000 claims description 41
-1 NRY1 RY2 Chemical group 0.000 claims description 40
108010082126 Alanine transaminase Proteins 0.000 claims description 30
102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 29
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 27
108091007780 MiR-122 Proteins 0.000 claims description 25
125000005842 heteroatom Chemical group 0.000 claims description 24
229910052760 oxygen Inorganic materials 0.000 claims description 24
210000002966 serum Anatomy 0.000 claims description 20
150000003839 salts Chemical group 0.000 claims description 18
229910052717 sulfur Inorganic materials 0.000 claims description 17
150000001875 compounds Chemical class 0.000 claims description 15
210000004185 liver Anatomy 0.000 claims description 15
125000000623 heterocyclic group Chemical group 0.000 claims description 14
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 13
210000004369 blood Anatomy 0.000 claims description 13
239000008280 blood Substances 0.000 claims description 13
210000002381 plasma Anatomy 0.000 claims description 13
102000004190 Enzymes Human genes 0.000 claims description 12
108090000790 Enzymes Proteins 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
201000007270 liver cancer Diseases 0.000 claims description 11
208000014018 liver neoplasm Diseases 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
229910052799 carbon Inorganic materials 0.000 claims description 9
229920006395 saturated elastomer Polymers 0.000 claims description 9
125000004432 carbon atom Chemical group C* 0.000 claims description 8
229910052736 halogen Inorganic materials 0.000 claims description 7
150000002367 halogens Chemical class 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 6
125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
125000004043 oxo group Chemical group O=* 0.000 claims description 6
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
229910052757 nitrogen Inorganic materials 0.000 claims description 5
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
125000002619 bicyclic group Chemical group 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
125000001188 haloalkyl group Chemical group 0.000 claims description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 3
125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
150000001602 bicycloalkyls Chemical group 0.000 claims description 3
125000003566 oxetanyl group Chemical group 0.000 claims description 3
125000004430 oxygen atom Chemical group O* 0.000 claims description 3
125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims description 2
VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims description 2
229920002905 Colesevelam Polymers 0.000 claims description 2
229920002911 Colestipol Polymers 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
229960001152 colesevelam Drugs 0.000 claims description 2
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims description 2
229960002604 colestipol Drugs 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 2
125000006413 ring segment Chemical group 0.000 claims description 2
125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 9
201000011510 cancer Diseases 0.000 abstract description 6
229940126062 Compound A Drugs 0.000 description 26
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 26
241001465754 Metazoa Species 0.000 description 24
108091051828 miR-122 stem-loop Proteins 0.000 description 21
206010073071 hepatocellular carcinoma Diseases 0.000 description 16
231100000844 hepatocellular carcinoma Toxicity 0.000 description 15
108010003415 Aspartate Aminotransferases Proteins 0.000 description 14
102000004625 Aspartate Aminotransferases Human genes 0.000 description 14
239000003981 vehicle Substances 0.000 description 14
239000003613 bile acid Substances 0.000 description 12
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 11
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 9
150000003254 radicals Chemical class 0.000 description 8
150000001721 carbon Chemical group 0.000 description 7
241000282472 Canis lupus familiaris Species 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
238000011084 recovery Methods 0.000 description 5
108091032955 Bacterial small RNA Proteins 0.000 description 4
150000001860 citric acid derivatives Chemical class 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
206010067125 Liver injury Diseases 0.000 description 3
108700011259 MicroRNAs Proteins 0.000 description 3
BHKDKKZMPODMIQ-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N BHKDKKZMPODMIQ-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000000090 biomarker Substances 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
231100000234 hepatic damage Toxicity 0.000 description 3
230000008818 liver damage Effects 0.000 description 3
239000002679 microRNA Substances 0.000 description 3
230000000116 mitigating effect Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
206010012735 Diarrhoea Diseases 0.000 description 2
229940125407 FGF401 Drugs 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
238000011278 co-treatment Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000012458 free base Substances 0.000 description 2
125000001183 hydrocarbyl group Chemical group 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
125000005936 piperidyl group Chemical group 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
230000036962 time dependent Effects 0.000 description 2
231100000607 toxicokinetics Toxicity 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
HUTNXAYRNHOZHL-UHFFFAOYSA-N 4-methyl-3h-1,3-oxazol-2-one Chemical compound CC1=COC(=O)N1 HUTNXAYRNHOZHL-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
206010069703 Bile acid malabsorption Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
108091008794 FGF receptors Proteins 0.000 description 1
102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 description 1
101100334744 Homo sapiens FGFR4 gene Proteins 0.000 description 1
101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
YJMPFOXUBAJFFA-UHFFFAOYSA-N [1,2]thiazolo[4,3-b]pyridine Chemical compound C1=CC=NC2=CSN=C21 YJMPFOXUBAJFFA-UHFFFAOYSA-N 0.000 description 1
230000009102 absorption Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
239000012620 biological material Substances 0.000 description 1
208000024330 bloating Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
230000005773 cancer-related death Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000007423 decrease Effects 0.000 description 1
OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000010235 enterohepatic circulation Effects 0.000 description 1
125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
208000018191 liver inflammation Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
230000007170 pathology Effects 0.000 description 1
RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
229940073095 questran Drugs 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229960003787 sorafenib Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000440 toxicity profile Toxicity 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ES17812269T 2016-11-02 2017-11-01 Combinaciones de inhibidores de FGFR4 y secuestrantes de ácidos biliares Active ES2934341T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662416222P	2016-11-02	2016-11-02
PCT/IB2017/056787 WO2018083603A1 (fr)	2016-11-02	2017-11-01	Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire

Publications (1)

Publication Number	Publication Date
ES2934341T3 true ES2934341T3 (es)	2023-02-21

Family

ID=60661908

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES17812269T Active ES2934341T3 (es)	2016-11-02	2017-11-01	Combinaciones de inhibidores de FGFR4 y secuestrantes de ácidos biliares

Country Status (17)

Country	Link
US (1)	US11229643B2 (fr)
EP (1)	EP3534902B1 (fr)
JP (2)	JP7394623B2 (fr)
KR (1)	KR102362648B1 (fr)
CN (2)	CN109922804B (fr)
AU (1)	AU2017354082B2 (fr)
CA (1)	CA3042475C (fr)
ES (1)	ES2934341T3 (fr)
IL (1)	IL266293B (fr)
MA (1)	MA46712A (fr)
MX (1)	MX387222B (fr)
PL (1)	PL3534902T3 (fr)
PT (1)	PT3534902T (fr)
RU (1)	RU2742033C2 (fr)
SG (1)	SG11201903911UA (fr)
WO (1)	WO2018083603A1 (fr)
ZA (1)	ZA201902744B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6585167B2 (ja)	2014-10-03	2019-10-02	ノバルティスアーゲー	Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
CN112759593A (zh) *	2019-11-01	2021-05-07	北京伯汇生物技术有限公司	桥环并醛基吡啶衍生物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2582652T3 (es)	2006-02-10	2016-09-14	Genentech, Inc.	Anticuerpos anti-FGF19 y métodos de uso de los mismos
EP1918376A1 (fr)	2006-11-03	2008-05-07	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	FGFR4 favorise la résistance des cellules cancéreuses en réponse aux agents chimiothérapeutiques
EP2124884B1 (fr) *	2006-12-22	2019-07-10	Ironwood Pharmaceuticals, Inc.	Compositions contenant des chelateurs d'acide biliaire pour le traitement des troubles oesphagiens
CL2008000947A1 (es)	2007-04-02	2008-10-10	Genentech Inc	Uso de un antagonista de la proteina beta-klotho (klb) para tratar trastornos asociados a la expresion o actividad de klb.
US8524212B2 (en) *	2007-10-24	2013-09-03	Mitsubishi Tanabe Pharma Corporation	Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
FR2933702A1 (fr)	2008-07-08	2010-01-15	Sanofi Aventis	Antagonistes specifiques du recepteur fgf-r4
WO2010026291A1 (fr)	2008-09-03	2010-03-11	Licentia Ltd.	Matières et procédés pour bloquer l'invasion par les cellules cancéreuses sur fgfr4
US20100330175A1 (en) *	2009-06-24	2010-12-30	Jobdevairakkam Christopher N	Cross-linked polyallylamine tablet core
CA2828890A1 (fr)	2011-04-07	2012-10-11	Genentech, Inc.	Anticorps anti-fgfr4 et procedes d'utilisation
MX347354B (es)	2011-08-17	2017-04-24	Ironwood Pharmaceuticals Inc	Tratamientos para trastornos gastrointestinales.
SG11201500125QA (en)	2012-07-11	2015-02-27	Blueprint Medicines Corp	Inhibitors of the fibroblast growth factor receptor
ES2915851T3 (es) *	2012-12-27	2022-06-27	Ngm Biopharmaceuticals Inc	Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
WO2014105849A1 (fr)	2012-12-28	2014-07-03	Xoma (Us) Llc	Anticorps spécifiques contre le fgfr4 et méthodes d'utilisation
WO2014165287A1 (fr)	2013-03-12	2014-10-09	The Translational Genomics Research Institute	Clones d'hybridome et anticorps monoclonaux dirigés contre le facteur de croissance 4 des fibroblastes
WO2014145909A2 (fr)	2013-03-15	2014-09-18	Dana-Farber Cancer Institute, Inc.	Composés pyrimido-diazépinone et procédés de traitement de troubles
CN105307657B (zh)	2013-03-15	2020-07-10	西建卡尔有限责任公司	杂芳基化合物和其用途
AR097455A1 (es)	2013-08-28	2016-03-16	Astellas Pharma Inc	Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
PH12016500676B1 (en)	2013-10-18	2022-07-20	Eisai R&D Man Co Ltd	Pyrimidine fgfr4 inhibitors
TN2016000115A1 (en)	2013-10-25	2017-07-05	Novartis Ag	Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
WO2015107171A1 (fr)	2014-01-17	2015-07-23	Sanofi	Méthodes d'identification de patients souffrant d'un cancer du foie pour lesquels un traitement avec un anticorps anti-fgfr4 antagoniste est plus à même d'être bénéfique
AU2015277438B2 (en) *	2014-06-16	2020-02-27	Ngm Biopharmaceuticals, Inc.	Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016023894A1 (fr)	2014-08-11	2016-02-18	U3 Pharma Gmbh	Anticorps anti-fgfr4 humain
JP6585167B2 (ja) *	2014-10-03	2019-10-02	ノバルティスアーゲー	Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
US20160115164A1 (en)	2014-10-22	2016-04-28	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI712601B (zh)	2015-02-20	2020-12-11	美商英塞特公司	作為fgfr抑制劑之雙環雜環
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
WO2016151501A1 (fr) *	2015-03-25	2016-09-29	Novartis Ag	Combinaisons pharmaceutiques
EP3095465A1 (fr) *	2015-05-19	2016-11-23	U3 Pharma GmbH	Combinaison d'un inhibiteur de fgfr4 et d'un chélateur d'acides biliaires

2017
- 2017-11-01 SG SG11201903911UA patent/SG11201903911UA/en unknown
- 2017-11-01 CN CN201780068265.7A patent/CN109922804B/zh active Active
- 2017-11-01 CN CN202311453574.XA patent/CN117257800A/zh active Pending
- 2017-11-01 MX MX2019005194A patent/MX387222B/es unknown
- 2017-11-01 KR KR1020197015424A patent/KR102362648B1/ko active Active
- 2017-11-01 ES ES17812269T patent/ES2934341T3/es active Active
- 2017-11-01 MA MA046712A patent/MA46712A/fr unknown
- 2017-11-01 JP JP2019523704A patent/JP7394623B2/ja active Active
- 2017-11-01 EP EP17812269.3A patent/EP3534902B1/fr active Active
- 2017-11-01 IL IL266293A patent/IL266293B/en unknown
- 2017-11-01 RU RU2019116061A patent/RU2742033C2/ru active
- 2017-11-01 CA CA3042475A patent/CA3042475C/fr active Active
- 2017-11-01 AU AU2017354082A patent/AU2017354082B2/en active Active
- 2017-11-01 US US16/347,194 patent/US11229643B2/en active Active
- 2017-11-01 PL PL17812269.3T patent/PL3534902T3/pl unknown
- 2017-11-01 WO PCT/IB2017/056787 patent/WO2018083603A1/fr not_active Ceased
- 2017-11-01 PT PT178122693T patent/PT3534902T/pt unknown
2019
- 2019-05-02 ZA ZA2019/02744A patent/ZA201902744B/en unknown
2021
- 2021-11-10 JP JP2021183688A patent/JP2022033766A/ja active Pending

Also Published As

Publication number	Publication date
JP7394623B2 (ja)	2023-12-08
US20200261444A1 (en)	2020-08-20
CN117257800A (zh)	2023-12-22
BR112019008787A2 (pt)	2019-07-16
CN109922804B (zh)	2023-11-17
SG11201903911UA (en)	2019-05-30
CN109922804A (zh)	2019-06-21
KR102362648B1 (ko)	2022-02-11
MX2019005194A (es)	2019-08-05
EP3534902A1 (fr)	2019-09-11
ZA201902744B (en)	2021-08-25
WO2018083603A1 (fr)	2018-05-11
AU2017354082A1 (en)	2019-05-23
RU2742033C2 (ru)	2021-02-01
IL266293A (en)	2019-06-30
MA46712A (fr)	2019-09-11
IL266293B (en)	2022-07-01
RU2019116061A3 (fr)	2020-12-04
CA3042475A1 (fr)	2018-05-11
PT3534902T (pt)	2022-12-07
PL3534902T3 (pl)	2023-03-27
MX387222B (es)	2025-03-18
JP2022033766A (ja)	2022-03-02
RU2019116061A (ru)	2020-12-04
AU2017354082B2 (en)	2023-07-27
EP3534902B1 (fr)	2022-11-23
KR20190082256A (ko)	2019-07-09
JP2019533701A (ja)	2019-11-21
CA3042475C (fr)	2024-01-16
US11229643B2 (en)	2022-01-25

Publication	Publication Date	Title
US20210251944A1 (en)	2021-08-19	Methods for treating a cancer resistant to at least one tyrosine kinase inhibitor
ES2856210T3 (es)	2021-09-27	Dosificación intermitente de inhibidor de mdm2
CA2914025C (fr)	2023-03-07	Utilisation de dianhydrogalacticol et d'analogues et de derives de celui-ci pour traiter un gliome malin recurrent ou une tumeur cerebrale secondaire progressive
Zhuang et al.	2012	Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model
KR20070007055A (ko)	2007-01-12	Ｔｇｆ-베타 억제제를 이용한 악성 신경교종의 치료법
ES2906763T3 (es)	2022-04-20	Terapia combinada de PAC-1
EA029072B1 (ru)	2018-02-28	Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
ES2934341T3 (es)	2023-02-21	Combinaciones de inhibidores de FGFR4 y secuestrantes de ácidos biliares
ES2702038T3 (es)	2019-02-27	Métodos de tratamiento de fibrosis y cánceres
CN119677507A (zh)	2025-03-21	治疗癌症的联合疗法
CN107137407B (zh)	2021-07-27	一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
HK40009437B (zh)	2024-05-10	Fgfr4抑制剂和胆汁酸螯合剂的组合
HK40009437A (en)	2020-06-26	Combinations of fgfr4 inhibitors and bile acid sequestrants
Telang et al.	2006	87 POSTER Ascorbate (vitamin C): friend or foe in the fight against cancer